文献速递骨肌技术与安全MRCT

新诊断四肢软组织肉瘤辅助容积旋转调强放疗与三维适形放疗的疗效及毒性比较

Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation.
PubMed 文献 · Br J Radiol · 2019-07-25

2004至2016年109例四肢软组织肉瘤患者术后接受辅助放疗,38例为三维适形放疗(3DCRT)、71例为容积旋转调强放疗(VMAT),VMAT组骨受量保护更优(p<0.001),全队列2年与5年局部控制率分别为95.3±2.1%与87.4±3.4%,组间比较p=0.150;作者认为VMAT安全可行、毒性有限,局部控制结果令人鼓舞。

要点

  • VMAT较3DCRT骨受量保护更成功(p<0.001),可减少骨高剂量照射以降低放射性骨坏死风险。
  • 全队列2年与5年局部控制率分别为95.3±2.1%与87.4±3.4%,3DCRT与VMAT组间比较p=0.150。
  • 手术切缘状态(p=0.028)与总剂量(p=0.013)是局部控制的 conditioning 因素。

核心结论

  • 现代放疗技术可使靶区适形性更好并最大限度保护正常组织、副作用可接受;VMAT安全可行、毒性发生率有限,局部控制结果令人鼓舞。

研究设计与样本

  • 2004至2016年109例四肢软组织肉瘤患者,先行3DCRT后改用VMAT,术后辅助3DCRT 38例、VMAT 71例,中位总剂量66 Gy/33次(范围60-70 Gy;25-35次),治疗后3个月及之后每6个月以增强MRI、胸部及腹部CT评估临床结局,毒性按不良事件通用术语标准v4.3评估。

诊断标准与关键数值

  • 全队列2年与5年局部控制率分别为95.3±2.1%与87.4±3.4%;3DCRT组分别为92.0±4.5%与82.9±6.4%,VMAT组分别为97.1±2.0%与89.6±4.1%(p=0.150);单因素与多因素分析中影响局部控制的因素为手术切缘状态(p=0.028)与总剂量(p=0.013)。

临床应用与阅片要点

  • 作者认为VMAT安全可行、毒性发生率有限,局部控制结果令人鼓舞;至少66 Gy的总剂量联合根治性手术切缘可获得良好局部控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the impact of adjuvant volumetric modulated arc therapy (VMAT) compared with three-dimensional conformal radiation therapy (3DCRT) in terms of toxicity and local control (LC) in patients with soft tissue sarcoma of the extremities.

METHODS: From 2004 to 2016, 109 patients were treated, initially using 3DCRT and subsequently with VMAT. Clinical outcome was evaluated by contrast-enhanced MRI, thoracic and abdominal CT 3 months after treatments and then every 6 months. Toxicity was evaluated with Common Terminology Criteria for Adverse Events scale v. 4.3.

RESULTS: Patients presented Stage III soft tissue sarcoma disease (77%), localized tumor (95%) at the lower extremity (87%), adipocytic histotype (46%). Surgical resection was performed in all patients, followed by adjuvant 3DCRT in 38, and VMAT in 71. The median total dose was 66 Gy/33 fractions (range 60-70 Gy;25-35 fractions). More successful bone sparing was recorded using VMAT (p < 0.001). Median follow-up was 61 months, 93 and 58 months for 3DCRT and VMAT group, respectively. The 2- and 5 year LC were 95.3±2.1%, and 87.4±3.4% for the whole cohort, 92.0±4.5%, 82.9±6.4% for 3DCRT, 97.1±2.0%, 89.6±4.1% for VMAT (p = 0.150). On univariate and multivariate analysis the factors recorded as conditioning LC were the status of the surgical resection margins (p = 0.028) and the total dose delivered (p = 0.013).

CONCLUSION: The availability of modern radiotherapy technique permit a better conformity on the target with maximum sparing of normal tissue and acceptable side-effects. VMAT is a safe and feasible treatment with limited rate of toxicity, compared to 3DCRT. Results on LC of VMAT are encouraging.

ADVANCES IN KNOWLEDGE: Soft tissue sarcoma of the extremities can benefit from the use of VMAT, with a reduction of the high dose to bones to avoid radiation osteonecrosis. An adequate total dose of at least 66 Gy and a radical surgical margin allow a good local control.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Di Brina L, Fogliata A, Navarria P, et al. Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. Br J Radiol. 2019. PMID: 31322910. doi:10.1259/bjr.20190252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。